-

Bayer Appoints Priyal Patel as Chief Financial Officer for North America

ST. LOUIS--(BUSINESS WIRE)--Bayer today announced the appointment of Priyal Patel as Cluster Chief Financial Officer (CFO) for North America, effective July 1, 2025. In her new role, Patel will oversee financial strategy and operations across Bayer’s North American businesses while continuing to serve as Head of Treasury for Bayer North America. She succeeds Guru Ramamurthy, who was recently appointed the new CFO for Bayer’s Crop Science division. With over two decades of experience, Patel brings deep financial expertise and a proven record of leadership.

Since joining Bayer in 2008, Patel has held a variety of finance leadership roles, including Finance Business Partner for the Crop Science division, Director of Investor Relations, and most recently, Head of North America Treasury. In this capacity, she led a strategic reorganization of the treasury team and developed innovative strategies to navigate volatile capital markets and support investment and insurance needs across the region.

“Priyal brings a deep understanding of our business, a strong track record of financial leadership, and a passion for driving transformation,” said Sebastian Guth, Chief Operating Officer, Bayer Pharmaceuticals and President of Bayer U.S. “Her commitment to excellence and her connection to the communities we serve make her an outstanding choice to lead our North America finance organization.”

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Contacts

Media Contact:
Nicole Hayes
201-421-5268
Nicole.Hayes@bayer.com

Bayer


Release Versions

Contacts

Media Contact:
Nicole Hayes
201-421-5268
Nicole.Hayes@bayer.com

More News From Bayer

Missouri Court Grants Preliminary Approval of Roundup™ Class Settlement to Resolve Current and Future Claims

ST. LOUIS--(BUSINESS WIRE)--Today, a judge in the Circuit Court of the City of St. Louis, Missouri granted preliminary approval of a class action settlement to resolve current and potential future Roundup claims alleging non-Hodgkin lymphoma (NHL) injuries. The motion was filed by leading plaintiff law firms representing the class. “We are pleased the Court granted preliminary approval of the class settlement, which is designed to resolve current and potential future Roundup claims relating to...

New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. This updated clearance expands MRXperion’s labeled field strength compatibility to support magnetic resonance imaging (MRI) scanners with magnetic...

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

BERLIN--(BUSINESS WIRE)--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy (TAT) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The dose for expansion was successfully identified, with ≥80% of patients achieving a PSA50 response at the expansion dose....
Back to Newsroom